Methods for treating coagulation disorders

• US 8,454,957 B2
• Filed: 06/17/2011
• Issued: 06/04/2013
• Est. Priority Date: 06/17/2010
• Status: Active Grant

• Current Assignee: Stemnion, Inc.
• Original Assignee: Stemnion, Inc.
• Inventors: Steed, David L., Golden, William J.
• Primary Examiner(s): Hill, Kevin
• Assistant Examiner(s): Leonard, Arthur S
• Application Number:
  US13/134,821
• Publication Number:
  US 20110311513A1
• Time in Patent Office: 718 Days
• Field of Search: None
• US Class Current: 424/130.1
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly

Abstract

The invention is directed to methods for treating coagulation disorders, in particular, hemophilia. Such methods utilize novel compositions including Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) alone or in combination with other agents and/or treatment modalities.

Claims

1. A method for treating Hemophilia A in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a substantially purified population of cultured non-genetically modified amnion-derived epithelial cells, wherein the amnion-derived epithelial cells are made by a method comprising the steps of

a) obtaining a placenta and isolating an amnion from the placenta,

b) enzymatically releasing amnion-derived epithelial cells from the amnion,

c) collecting the released amnion-derived epithelial cells, and

d) culturing the collected amnion-derived epithelial cells of step (c) in basal culture medium that is supplemented with human serum albumin and recombinant human EGF.

2. The method of claim 1 wherein the amnion-derived epithelial cells are pooled amnion-derived epithelial cells.

3. The method of claim 1 wherein the amnion-derived epithelial cells are administered in combination with another agent or treatment modality.

4. The method of claim 3 wherein the other agent is selected from the group consisting of dietary supplementation or replacement, vitamins, intermediary metabolites, compounds or drugs that facilitate or retard specific metabolic pathways, enzyme replacement, cytokines, chemokines, antibodies, inhibitors, antibiotics, anti-fungals, anti-virals, immunosuppressive agents, and other cell types.

5. The method of claim 1 wherein the administration is selected from the group consisting of intravenous injection, intraarterial injection, intramuscular injection, intrathecal injection, epidural injection, transplantation into an organ or tissue, and infusion.